Anhco Nguyen Sells 1,664 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Anhco Nguyen sold 1,664 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $11.20, for a total value of $18,636.80. Following the transaction, the chief executive officer now owns 77,454 shares in the company, valued at $867,484.80. This represents a 2.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Atara Biotherapeutics Trading Down 2.8 %

NASDAQ:ATRA opened at $10.68 on Thursday. Atara Biotherapeutics, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $39.50. The stock has a fifty day moving average price of $9.14 and a 200-day moving average price of $10.11.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The firm had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same period in the previous year, the business posted ($16.50) earnings per share. Analysts expect that Atara Biotherapeutics, Inc. will post -12.12 earnings per share for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its stake in Atara Biotherapeutics by 29.3% in the first quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 86,842 shares during the last quarter. Acadian Asset Management LLC raised its stake in Atara Biotherapeutics by 49.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock valued at $1,830,000 after acquiring an additional 873,133 shares during the period. Delap Wealth Advisory LLC purchased a new stake in shares of Atara Biotherapeutics during the 1st quarter valued at approximately $29,000. Price T Rowe Associates Inc. MD grew its stake in Atara Biotherapeutics by 8,916.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after buying an additional 4,903,159 shares in the last quarter. Finally, Redmile Group LLC lifted its position in shares of Atara Biotherapeutics by 1.7% during the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock worth $6,429,000 after acquiring an additional 156,863 shares in the last quarter. 70.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. HC Wainwright reissued a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. Canaccord Genuity Group lifted their price objective on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their price objective for the stock from $25.00 to $18.00 in a report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $16.67.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.